Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Active:	No
Cancer Type:	Solid Tumor	NCT ID:	NCT06343792
Trial Phases:	Phase II	Protocol IDs:	RLS-0071-203 (primary) NCI-2024-05325
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	ReAlta Life Sciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06343792

Summary

This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to
Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy
of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in
hospitalized patients who are steroid-refractory.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.